Printing of Biogels for enhanced antibiotic susceptibility measurements

打印生物凝胶以增强抗生素敏感性测量

• 批准号: 10062001
• 金额: $ 2.53万
• 依托单位: MICROPLATE DX LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10062001
• 关键词: Printing; Biogels; enhanced; antibiotic; susceptibility

Resistance to antibiotics is one of the most concerning challenges society currently faces. It is on a par with climate change and accumulation of plastic in the ocean. It is a reflection on the importance of this challenge that many new technologies are being developed to help doctors select the correct antibiotic for a given infection. The misdirected use of antibiotics is one of the drivers of antibiotic resistance, inappropriate prescriptions increase the number of drug resistant infections and accelerate the process of reaching the point where current medicines no longer work.Microplate Dx is a company attempting to address this issue through an innovative technological solution which effectively shrinks traditional microbial culture on large agar plates down on to a microchip style technology and allows the resistance pattern of bacteria causing the infection to be determined. This allows clinicians to make informed decisions about which drug to prescribe in under one hour. Technologies like this will have a big role to play in improving 'antibiotic stewardship' and preserving the stocks of medicine we currently have.To take the Microplate Dx prototype from concept to reality it is necessary to address several measurement issues around the product itself so that its manufacturability and scalability can be properly demonstrated. Showing that the gel deposits, which go onto the chip can be deposited with high consistency is crucial to demonstrating manufacturability and also, being able to show that the various chemicals added to the gel which make the test work are evenly distributed throughout is a key performance factor which needs to be verified.In this project, Microplate Dx will work with the National Measurement Laboratory who through access to their biological printer and surface characterisation instrumentation will assist with these two challenges. Achieving these goals will help the company with moving its technological development forward and sourcing future investments and revenue.

抗生素耐药性是当今社会面临的最大挑战之一。这与气候变化和海洋中塑料的积累相当。许多新技术正在开发，以帮助医生为特定感染选择正确的抗生素，这反映了这一挑战的重要性。抗生素的错误使用是抗生素耐药性的驱动因素之一，不适当的处方增加了耐药感染的数量，并加速了达到目前药物不再起作用的程度的过程。Microplate Dx是一家试图通过创新的技术解决方案来解决这个问题的公司，该解决方案有效地将传统的微生物培养在大琼脂平板上缩小到微芯片式技术，允许确定引起感染的细菌的抗性模式。这使得临床医生能够在一小时内做出关于开哪种药物的明智决定。像这样的技术将在改善“抗生素管理”和保护我们现有的药物库存方面发挥重要作用。为了将Microplate Dx原型从概念变为现实，有必要解决产品本身的几个测量问题，以便正确展示其可制造性和可扩展性。显示凝胶沉积物（其可以高一致性地沉积到芯片上）对于证明可制造性至关重要，并且能够显示添加到凝胶中的使测试工作均匀分布的各种化学品是需要验证的关键性能因素。在该项目中，Microplate Dx将与国家测量实验室合作，该实验室将通过使用其生物打印机和表面表征仪器来协助应对这两项挑战。实现这些目标将有助于公司推进技术发展，并寻求未来的投资和收入。